Literature DB >> 11100913

Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection.

M Mukhtar1, R J Pomerantz.   

Abstract

OBJECTIVE: An in vitro blood-brain barrier (BBB) system was developed using primary cultures of human brain-derived microvascular endothelial cells (MVECs), macrophages, neuronal cells, and human fetal astrocytes. This BBB system simulates important morphologic and permeability characteristics of the BBB in vivo. This system could be used to study human neurologic/neurovirologic disorders. STUDY DESIGN AND METHODS: Microvascular endothelial cells were cultured to 100% confluency on the upper side of 0.45-microm polyethylene tetraphthalte (PET) membrane inserts coated with MVEC attachment factor. Expression of ZO-1 (Zona Occludens 1), a protein specifically associated with tight junctions and the intercellular sealing of adjacent MVECs, was analyzed by immunocytochemical methods. The integrity of the BBB formed on the insert membrane was also assessed by the measurement of electrical current passage through the membrane; and, after the formation of complete BBB, a two-compartment system was developed using the cell culture insert upper surface, essentially a confluent monolayer of brain-derived MVECs housed on a six-well chamber surface. In the six-well chamber surface, there are different central nervous system (CNS)-based cells, ie, human astrocytes, immature neurons, mature neurons, and MVEC. The cell culture inserts were in close juxtaposition to the surface of the chamber, making an intimate contact with the cells, separated by an insert membrane. The MVEC surface of the insert was exposed to human immunodeficiency virus type 1 (HIV-1) strains 89.6, NL4-3, and IIIB. After 72 hours, the cells were fixed and used for in situ polymerase chain reaction (IS-PCR), whereas the supernatant was subjected to HIV-1 p24 antigen determination.
RESULTS: Primary human brain MVECs are capable of forming tight junctions, revealed by the expression of ZO-1, as well as elevated transendothelial electrical resistance. Based on these characteristics, these cells formed an in vitro BBB, which then was used to study the transfer of HIV-1 through this barrier. It was observed that HIV-1 can infect MVEC and can cross it in vitro and infect the cells growing on the opposite side of the membrane. Infection of various CNS-based cells was confirmed by IS-PCR, as well as by HIV-1 p24-antigen determination. It was observed that the dual-tropic strain, 89.6, had a greater potential to create a breach in the in vitro BBB, followed by NL4-3 and IIIB.
CONCLUSION: This model system is relevant for evaluating HIV-1 neuropathogenesis and therapeutics designed to alter HIV-1 expression in human CNS-based cells. As such, the effects of highly active antiretroviral therapy on HIV-1 infection of the human CNS, a possible drug sanctuary site, can be evaluated using this technology.

Entities:  

Mesh:

Year:  2000        PMID: 11100913

Source DB:  PubMed          Journal:  J Hum Virol        ISSN: 1090-9508


  15 in total

Review 1.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells.

Authors:  Rachel C Brown; Andrew P Morris; Roger G O'Neil
Journal:  Brain Res       Date:  2006-12-12       Impact factor: 3.252

3.  Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.

Authors:  Edward A Acheampong; Zahida Parveen; Lois W Muthoga; Vivian Wasmuth-Peroud; Mehrnush Kalayeh; Adnan Bashir; Robert Diecidue; Muhammad Mukhtar; Roger J Pomerantz
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.

Authors:  Edward A Acheampong; Zahida Parveen; Lois W Muthoga; Mehrnush Kalayeh; Muhammad Mukhtar; Roger J Pomerantz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.

Authors:  Edward Acheampong; Zahida Parveen; Aschalew Mengistu; Noel Ngoubilly; Brian Wigdahl; Albert S Lossinsky; Roger J Pomerantz; Muhammad Mukhtar
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 6.  Human brain derived cell culture models of HIV-1 infection.

Authors:  P Seth; E O Major
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

7.  Lentiviral expression of HIV-1 Vpr induces apoptosis in human neurons.

Authors:  Charvi A Patel; Muhammad Mukhtar; Stephen Harley; Joseph Kulkosky; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

8.  West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier.

Authors:  Saguna Verma; Yeung Lo; Moti Chapagain; Stephanie Lum; Mukesh Kumar; Ulziijargal Gurjav; Haiyan Luo; Austin Nakatsuka; Vivek R Nerurkar
Journal:  Virology       Date:  2009-01-10       Impact factor: 3.616

9.  The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system.

Authors:  Elias G Argyris; Edward Acheampong; Fengxiang Wang; Jialing Huang; Keyang Chen; Muhammad Mukhtar; Hui Zhang
Journal:  Virology       Date:  2007-07-12       Impact factor: 3.616

10.  Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts.

Authors:  Elias G Argyris; Edward Acheampong; Giuseppe Nunnari; Muhammad Mukhtar; Kevin Jon Williams; Roger J Pomerantz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.